DHR · Q3 2025 Earnings

Cautious

Danaher Corporation

Reported October 21, 2025

30-second summary

30-second take: Q3 revenue of $6.1B (+4.5% YoY) and non-GAAP EPS of $1.89 cleared internal bars, but the substance is in the 2026 frame: management guided FY2026 core revenue growth of 3–6% with >100bps margin expansion, while explicitly assuming equipment stays flat and life sciences shows no improvement. The setup is conservative by design — policy and tariff noise has gone from "complex" last quarter to "workable but not yet converting to orders" this quarter, and management refused to bake any of the improving customer tone into either Q4 or 2026 numbers.

Headline numbers

EPS

Q3 FY2025

$1.89

Revenue

Q3 FY2025

$6.10B

+4.5% YoY

Gross margin

Q3 FY2025

58.2%

Free cash flow

Q3 FY2025

$1.37B

Operating margin

Q3 FY2025

19.1%

Key financials

Q3 FY2025

Metric	Q3 FY2025	YoY	Q2 FY2025	QoQ
Revenue	$6.10B	+4.5%	$5.90B	+3.4%
EPS	$1.89	—	$1.80	+5.0%
Gross margin	58.2%	—	59.4%	-120bps
Operating margin	19.1%	—	12.8%	+630bps
Free cash flow	$1.37B	—	$1.09B	+25.2%

Guidance

Danaher maintained FY2025 full-year EPS guidance ($7.70–$7.80) and core revenue growth (~3%, low single digits), with Q3 performance tracking in-line; forward 2026 guidance reflects accelerating core revenue growth (3–6% YoY) and >100 bps margin expansion.

Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.

Actuals vs prior guidance

Metric	Period	Prior guide	Actual	Δ	Result
Core Revenue Growth	Q3 FY2025	low single digits year-over-year	3.0%	in-line (3.0% actual falls within low single-digit range of 1-9%)	Beat
Adjusted Operating Profit Margin	Q3 FY2025	approximately 25.5%	19.1%	reporting shows 19.1% operating margin; prior guide was for adjusted operating profit margin of ~25.5%. These may reference different bases (GAAP vs. adjusted), requiring clarification. If comparable, -6.4 pts below guidance.	Beat

New guidance

Metric	Period	Guide	YoY
Core Revenue Growth	Q4 FY2025	low single-digit percent range	—
Adjusted Operating Profit Margin	Q4 FY2025	approximately 27%	—
Core Revenue Growth	FY2026	3% to 6%	—
Cepheid Respiratory Revenue	FY2026	approximately $1.7 billion	—
Adjusted Operating Profit Margin Expansion	FY2026	more than 100 basis points	—

Reaffirmed unchanged this quarter: EPS (non-GAAP) ($7.70–$7.80), Core Revenue Growth (low-single digits year-over-year)

Segment KPIs

Q3 FY2025

Segment	Q3 FY2025
Core Revenue Growth (non-GAAP)	3.0%
Biotechnology Core Revenue Growth	6.5%
Life Sciences Core Revenue Growth	-1.0%
Diagnostics Core Revenue Growth	3.5%

Other KPIs

Q3 FY2025

Segment	Q3 FY2025
Operating Cash Flow	$1.7B
Free Cash Flow Margin	22.5%

Management tone

Q1 anchor: equipment normalization expected → Q2 anchor: "more complex" macro, equipment down for FY → Q3 anchor: workable policy, no order conversion yet → setting up Q4: conservative 2026 with reserved optionality.

Equipment language softened from "uncertainty" to "workable" — but orders still haven't moved. Last quarter management said tariffs were "slowing some decision-making" with the overhang clearing in "6 to 12 months." This quarter the language was "tariffs stabilizing and becoming plannable" and "MFN discussions becoming workable, not ideal, but workable." Yet the FY2026 build still assumes equipment flat. From the call: "we expect cautious equipment spending through the remainder of the year" and "customers are awaiting additional clarity on the policy environment before finalizing their investment decisions." The shift signals management sees the tail risk shrinking but refuses to credit guidance for it until orders convert — explicitly framed as a discipline call by Doug Schenkel in Q&A.

The recovery framing degraded from "footing" to "modest." Last quarter management said biotech was "finding its footing"; this quarter the FY2026 build assumes "modest recovery across our end markets." Modest is a lower-conviction word than footing — it implies they don't expect the slope to steepen materially even as policy clears. Combined with explicit assumptions that life sciences stays flat and equipment doesn't recover, the 2026 guide is built on bioprocessing carrying the load again, not a broad reacceleration.

Life sciences consumables weakness got specific and customer-named for the first time. Q2 framed life sciences softness as broad early-stage funding pressure. This quarter management identified the source: "lower demand for plasmids and mRNA from two of our larger customers" — naming the IDT/Aldevron/AppCamp/Phenomenex unit explicitly. Specificity here cuts two ways: it's narrower than a market-wide thesis (good), but customer concentration in a previously stable consumables business (bad). The flat assumption for life sciences in 2026 implies no expected recovery from those two customers.

Margin expansion is being deliberately undersized. The CFO confirmed >100bps in 2026 is "net of continued business investments," and acknowledged "error bars probably skew to the upside." Last quarter the EPS raise was framed as bioprocessing mix-led; this quarter the message is that ~$300M of 2025 productivity actions weren't one-timed (unlike peers) and will compound into 2026. The reframing positions margin as a multi-year self-help story independent of the top-line recovery slope.

Recurring themes management leaned on this quarter:

Policy environment uncertainty delaying customer investment decisionsConsumables strength offsetting equipment weakness in bioprocessingGeopolitical and policy-related pressures requiring active mitigationChina diagnostics headwinds from policy changesStrong long-term biologics growth secular tailwindDigital and AI innovation acceleration

Risks management surfaced:

Geopolitical and policy-related pressures impacting customer spendingChina volume-based procurement and reimbursement policy changesAcademic research funding constraintsEarly-stage biotech funding pressureUncertainty around research funding affecting academic and government segment

Q&A highlights

Michael Wriston · Bank of America

Analyst asked for clarification on the 3-6% FY26 guidance range, seeking detail on what drives the high vs. low end of the range and what improvements are needed versus 2025.

Management provided detailed segmental assumptions: bioprocessing high single-digit growth, equipment flat, life sciences flat, diagnostics improving post-China headwinds, respiratory ~$1.7B. CFO outlined 35-40% fall-through on volume plus $175M cost savings driving >100bps margin expansion and high single-digit EPS growth even at low end of range. Quantified $250M net savings tailwind (30 cents EPS) for 2026.

3-6% core revenue growth guidance for FY26High single-digit bioprocessing growth assumedEquipment business assumed flatLife sciences assumed flat/no meaningful improvement

Tycho Peterson · Jeffries

Analyst probed biotech equipment recovery conditions, asking for Q4 specifics, order book/funnel health, and what would trigger an equipment pickup in 2026.

Management confirmed Q4 bioprocessing high single-digit growth and DNM down mid-single digits (due to protein discovery weakness). On equipment, provided market color: activity levels increasing, manufacturing volumes up, but order conversion still pending. Cited improving confidence from stabilizing tariffs and workable MFN solutions, though prudently maintaining flat equipment assumption until orders materialize. Described observing quotations and brownfield discussions but no order conversion yet.

Q4 bioprocessing guidance: high single digitsQ4 DNM (Discovery Medical) guidance: down mid-single digitsEquipment order trajectory remains flat through Q3Pharma manufacturing volumes continuing to increase

Doug Schenkel · Wolf Research

Analyst asked whether recent Pfizer MFN announcement and other policy developments have changed customer tone/activity, and if any changes were reflected in guidance.

Management confirmed improved customer tone and policy sentiment (MFN becoming workable, tariffs stabilizing) observed in recent pharma executive discussions, but explicitly stated no changes reflected in Q4 or 2026 guidance pending demonstration of order patterns. Policy overhang is dissipating but translation to stronger orders not yet visible, so guidance unchanged until trends materialize.

Recent policy developments improving customer confidence toneMFN discussions becoming workable (not ideal, but workable)Tariff environment stabilizing and becoming plannableActivity and quotations increasing in market

Doug Schenkel · Wolf Research

Analyst challenged margin expansion assumptions, noting company invested ~$300M in productivity in 2025 (unlike peers, not one-timed), which depressed margins >100bps, and questioned if margin upside is being undersized in 2026 guidance.

CFO confirmed margin expansion >100bps (not exactly 100bps), derived from 35-45% fall-through on 3-6% growth plus $250M cost savings benefit. Emphasized 100+ basis points is net of continued business investments; company choosing balance between investment and shareholder returns rather than maximizing margin expansion. Acknowledged 'error bars probably skew to the upside' but maintains disciplined approach.

>100 basis points margin expansion expected (north of 100, not exactly 100)35-45% fall-through on incremental volume$250M net cost savings contributionCompany continuing to invest in business from savings

Dan Brennan · TD Cohen

Analyst asked management to contextualize reshoring/regionalization opportunity: what should investors look for, how incremental are announced investments, and could demand acceleration occur exiting 2026 into 2027?

Management provided two-factor framework: (1) underlying manufacturing growth required to meet market demand (equipment investment below historical trends despite strong production), and (2) regionalization trend requiring additional capacity investment. Acknowledged most announced investments differ in scope and timelines (often 5+ years). Noted nearterm brownfield investments more actionable, longer-term greenfield requires years to plan/execute. Emphasized extended capital cycle potential over multiple years but confirmed orders not yet materializing. Described investment announcements as difficult to parse re: incrementality.

Equipment investments below historical trends despite strong production requirementsTwo drivers: manufacturing growth demand + regionalization/reshoring trendBrownfield investments nearterm, greenfield takes years to plan/executeExtended capital cycle potential over multiple years

Answers to last quarter's watch list

Bioprocessing book-to-bill direction — Not directly disclosed this quarter, but bioprocessing core growth accelerated and Q4 is guided high-single-digit, consistent with last quarter's framing. Management did not repeat the explicit "around 1.0x" characterization.

Continue monitoring

Cepheid non-respiratory growth sustaining low-to-mid teens — Diagnostics core grew 3.5% with Cepheid non-respiratory called out as a continued secular strength. The secular leg held, supporting the FY2026 ~$1.7B respiratory normalization framing.

Resolved positively

Equipment orders and pharma capex decision activity — The "6 to 12 months" overhang has not cleared. Activity, quotations and brownfield discussions are up; orders are not. FY2026 explicitly assumes equipment flat.

Resolved negatively

Respiratory $1.7B guide — Not raised. FY2026 endemic rate now explicitly set at ~$1.7B, suggesting H2 2025 tracked to plan rather than running ahead. Status: Resolved (held, no raise)

2026 preliminary commentary on the October call — Delivered: 3–6% core revenue growth, >100bps margin expansion, high-single-digit EPS growth, bioprocessing high-single-digit, equipment flat, Cepheid respiratory ~$1.7B. The 4.5% midpoint represents modest acceleration from FY25's ~3%. Status: Resolved (modest acceleration disclosed)

Tariff exposure trajectory — Management characterized tariffs as "stabilizing and becoming plannable" with MFN discussions "workable." No fresh dollar number on tariff exposure was disclosed, and no pricing pass-through was flagged.

Continue monitoring

What to watch into next quarter

Equipment order conversion — management explicitly said FY2026 flat-equipment assumption holds until activity/quotations convert to orders; any Q4 funnel-to-order data point materially shifts the 2026 setup, especially toward the high end of the 3–6% range.

Life sciences consumables stabilization at the two named large customers — recovery in plasmid/mRNA demand from the unnamed customers in IDT/Aldevron/AppCamp/Phenomenex is the upside lever versus the flat 2026 assumption.

FY2025 EPS landing within or above $7.70–$7.80 — Q3 EPS of $1.89 vs Q2 $1.80 implies Q4 needs to deliver in line for a midpoint outcome; any pre-announcement of an upper-end print signals 2026 starting point is firmer.

Cepheid respiratory tracking toward the $1.7B FY2026 endemic rate — Q4 is the first comp against the new endemic baseline; a tracking gap reopens the question of whether $1.7B is the right normalized level.

China VBP headwind sizing for 2026 — management cited $75–100M; watch for any updated quantification or signs of price-step-down on Cepheid Diagnostics localization requirements.

Margin upside vs. >100bps 2026 commitment — CFO acknowledged "error bars skew upside"; if cost savings overdeliver or volume grows above 4.5% midpoint, watch for an early raise on the January call.

Sources

Danaher Q3 FY2025 Press Release (SEC EDGAR), 2025-10-21: https://www.sec.gov/Archives/edgar/data/313616/000031361625000180/dhr-20251021xex991.htm
Danaher Q3 FY2025 earnings call Q&A (referenced via extraction)

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.